TY - JOUR
T1 - Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator
T2 - a prospective, controlled, multicentre cohort study
AU - Bauer, Axel
AU - Klemm, Mathias
AU - Rizas, Konstantinos D.
AU - Hamm, Wolfgang
AU - von Stülpnagel, Lukas
AU - Dommasch, Michael
AU - Steger, Alexander
AU - Lubinski, Andrezej
AU - Flevari, Panagiota
AU - Harden, Markus
AU - Friede, Tim
AU - Kääb, Stefan
AU - Merkely, Bela
AU - Sticherling, Christian
AU - Willems, Rik
AU - Huikuri, Heikki
AU - Malik, Marek
AU - Schmidt, Georg
AU - Zabel, Markus
AU - Merkely, Béla
AU - Perge, Peter
AU - Sallo, Zoltan
AU - Szeplaki, Gabor
AU - Lüthje, Lars
AU - Schlögl, Simon
AU - Haarmann, Helge
AU - Bergau, Leonard
AU - Seegers, Joachim
AU - Hasenfuß, Gerd
AU - Munoz-Exposito, Pascal
AU - Tichelbäcker, Tobias
AU - Kirova, Aleksandra
AU - Hnatkova, Katerina
AU - Vos, Marc
AU - Willich, Stefan N.
AU - Reinhold, Thomas
AU - Vandenberk, Bert
AU - Klinika, Magdalena
AU - Toplice, Krapinske
AU - Flevari, Panayota
AU - Katsimardos, Andreas
AU - Katsaras, Dimitrios
AU - Hatala, Robert
AU - Svetlosak, Martin
AU - Lubinski, Andrzej
AU - Kuczejko, Tomasz
AU - Hansen, Jim
AU - Conen, David
AU - Milosrdnice, Sestre
AU - Tuinenburg, Anton
N1 - Funding Information:
The study was funded by the European Community's 7th Framework Programme (HEALTH-F2-2009-602299) for 5 years (starting Oct 1, 2013).
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/10/12
Y1 - 2019/10/12
N2 - BACKGROUND: A small proportion of patients undergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant arrhythmias. We postulated that periodic repolarisation dynamics, a novel marker of sympathetic-activity-associated repolarisation instability, could be used to identify electrically vulnerable patients who would benefit from prophylactic implantation of ICDs by way of a reduction in mortality.METHODS: We did a prespecified substudy of EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigator-initiated, non-randomised, controlled cohort study done at 44 centres in 15 EU countries. Patients aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced left ventricular ejection fraction (≤35%) were eligible for inclusion if they met guideline-based criteria for primary prophylactic implantation of ICDs. Periodic repolarisation dynamics from 24-h Holter recordings were assessed blindly in patients the day before ICD implantation or on the day of study enrolment in patients who were conservatively managed. The primary endpoint was all-cause mortality. Propensity scoring and multivariable models were used to assess the interaction between periodic repolarisation dynamics and the treatment effect of ICDs on mortality.FINDINGS: Between May 12, 2014, and Sept 7, 2018, 1371 patients were enrolled in our study. 968 of these patients underwent ICD implantation, and 403 were treated conservatively. During follow-up (median 2·7 years [IQR 2·0-3·3] in the ICD group and 1·2 years [0·8-2·7] in the control group), 138 (14%) patients died in the ICD group and 64 (16%) patients died in the control group. We noted a 43% reduction in mortality in the ICD group compared with the control group (adjusted hazard ratio [HR] 0·57 [95% CI 0·41-0·79]; p=0·0008). Periodic repolarisation dynamics significantly predicted the treatment effect of ICDs on mortality (adjusted p=0·0307). The mortality benefits associated with ICD implantation were greater in patients with periodic repolarisation dynamics of 7·5 deg or higher (n=199; adjusted HR 0·25 [95% CI 0·13-0·47] for the ICD group vs the control group; p<0·0001) than in those with periodic repolarisation dynamics less than 7·5 deg (n=1166; adjusted HR 0·69 [95% CI 0·47-1·00]; p=0·0492; p
interaction=0·0056). The number needed to treat was 18·3 (95% CI 10·6-4895·3) in patients with periodic repolarisation dynamics less than 7·5 deg and 3·1 (2·6-4·8) in those with periodic repolarisation dynamics of 7·5 deg or higher.
INTERPRETATION: Periodic repolarisation dynamics predict mortality reductions associated with prophylactic implantation of ICDs in contemporarily treated patients with ischaemic or non-ischaemic cardiomyopathy. Periodic repolarisation dynamics could help to guide treatment decisions about prophylactic ICD implantation.FUNDING: The European Community's 7th Framework Programme.
AB - BACKGROUND: A small proportion of patients undergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant arrhythmias. We postulated that periodic repolarisation dynamics, a novel marker of sympathetic-activity-associated repolarisation instability, could be used to identify electrically vulnerable patients who would benefit from prophylactic implantation of ICDs by way of a reduction in mortality.METHODS: We did a prespecified substudy of EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigator-initiated, non-randomised, controlled cohort study done at 44 centres in 15 EU countries. Patients aged 18 years or older with ischaemic or non-ischaemic cardiomyopathy and reduced left ventricular ejection fraction (≤35%) were eligible for inclusion if they met guideline-based criteria for primary prophylactic implantation of ICDs. Periodic repolarisation dynamics from 24-h Holter recordings were assessed blindly in patients the day before ICD implantation or on the day of study enrolment in patients who were conservatively managed. The primary endpoint was all-cause mortality. Propensity scoring and multivariable models were used to assess the interaction between periodic repolarisation dynamics and the treatment effect of ICDs on mortality.FINDINGS: Between May 12, 2014, and Sept 7, 2018, 1371 patients were enrolled in our study. 968 of these patients underwent ICD implantation, and 403 were treated conservatively. During follow-up (median 2·7 years [IQR 2·0-3·3] in the ICD group and 1·2 years [0·8-2·7] in the control group), 138 (14%) patients died in the ICD group and 64 (16%) patients died in the control group. We noted a 43% reduction in mortality in the ICD group compared with the control group (adjusted hazard ratio [HR] 0·57 [95% CI 0·41-0·79]; p=0·0008). Periodic repolarisation dynamics significantly predicted the treatment effect of ICDs on mortality (adjusted p=0·0307). The mortality benefits associated with ICD implantation were greater in patients with periodic repolarisation dynamics of 7·5 deg or higher (n=199; adjusted HR 0·25 [95% CI 0·13-0·47] for the ICD group vs the control group; p<0·0001) than in those with periodic repolarisation dynamics less than 7·5 deg (n=1166; adjusted HR 0·69 [95% CI 0·47-1·00]; p=0·0492; p
interaction=0·0056). The number needed to treat was 18·3 (95% CI 10·6-4895·3) in patients with periodic repolarisation dynamics less than 7·5 deg and 3·1 (2·6-4·8) in those with periodic repolarisation dynamics of 7·5 deg or higher.
INTERPRETATION: Periodic repolarisation dynamics predict mortality reductions associated with prophylactic implantation of ICDs in contemporarily treated patients with ischaemic or non-ischaemic cardiomyopathy. Periodic repolarisation dynamics could help to guide treatment decisions about prophylactic ICD implantation.FUNDING: The European Community's 7th Framework Programme.
KW - Aged
KW - Arrhythmias, Cardiac/mortality
KW - Cardiomyopathies/complications
KW - Cohort Studies
KW - Death, Sudden, Cardiac/prevention & control
KW - Defibrillators, Implantable
KW - Electric Countershock
KW - Europe
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Propensity Score
KW - Stroke Volume
UR - http://www.scopus.com/inward/record.url?scp=85072928936&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(19)31996-8
DO - 10.1016/S0140-6736(19)31996-8
M3 - Article
C2 - 31488371
AN - SCOPUS:85072928936
SN - 0140-6736
VL - 394
SP - 1344
EP - 1351
JO - The Lancet
JF - The Lancet
IS - 10206
ER -